Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents. Their study is published in Clinical Cancer Research...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment